BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35532298)

  • 1. Smoldering multiple myeloma: Reviewing the rationale for intervention.
    Gertz M
    Leuk Lymphoma; 2022 Sep; 63(9):2033-2040. PubMed ID: 35532298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
    Rajkumar SV; Bergsagel PL; Kumar S
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):293-303. PubMed ID: 38158241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in the Management of Smoldering Multiple Myeloma.
    Schmidt TM; Callander NS
    Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
    Schmidt T; Callander N
    J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper.
    Hughes D; Yong K; Ramasamy K; Stern S; Boyle E; Ashcroft J; Basheer F; Rabin N; Pratt G
    Br J Haematol; 2024 Apr; 204(4):1193-1206. PubMed ID: 38393718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
    González-Calle V; Mateos MV
    Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
    Kunacheewa C; Manasanch EE
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smoldering multiple myeloma 40 years later: a story of unintended disease.
    Yavorkovsky LL
    Expert Rev Hematol; 2021 Feb; 14(2):149-153. PubMed ID: 33430658
    [No Abstract]   [Full Text] [Related]  

  • 9. Smoldering multiple myeloma current treatment algorithms.
    Rajkumar SV; Kumar S; Lonial S; Mateos MV
    Blood Cancer J; 2022 Sep; 12(9):129. PubMed ID: 36064707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The difficult business of assessing new therapies for smouldering multiple myeloma.
    Zonder JA
    Br J Haematol; 2018 Aug; 182(4):463-464. PubMed ID: 29767407
    [No Abstract]   [Full Text] [Related]  

  • 11. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
    Maciocia N; Wechalekar A; Yong K
    Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoldering multiple myeloma - Past, present, and future.
    Mann H; Katiyar V; Varga C; Comenzo RL
    Blood Rev; 2022 Mar; 52():100869. PubMed ID: 34312016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
    Musto P; Engelhardt M; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS
    Haematologica; 2021 Nov; 106(11):2799-2812. PubMed ID: 34261295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Stratification of Precursors to Multiple Myeloma in 2020.
    Chudasama R; Barth P
    R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Smoldering multiple myeloma].
    Fouquet G; Guidez S; Herbaux C; Demarquette H; Leleu X
    Rev Med Interne; 2014 Apr; 35(4):243-9. PubMed ID: 24050785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoldering multiple myeloma: biology, clinical manifestations and management.
    Nsiala L; Bobin A; Levy A; Gruchet C; Sabirou F; Gardeney H; Cailly L; Manier S; Moya N; Tomowiak C; Guidez S; Leleu X; Decaux O
    Leuk Lymphoma; 2022 Mar; 63(3):518-529. PubMed ID: 34672244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.
    Bladé J; Rosiñol L
    Curr Treat Options Oncol; 2006 May; 7(3):237-45. PubMed ID: 16615879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smouldering multiple myeloma: To seek or not to seek? To treat or not to treat. That is the question.
    Vaxman I; Gatt ME
    Br J Haematol; 2024 Apr; 204(4):1141-1142. PubMed ID: 38429858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
    Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions.
    Chojnacka M; Diamond B; Landgren O; Maura F
    Semin Oncol; 2022 Feb; 49(1):11-18. PubMed ID: 35168813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.